Unique Migraine Treatment Now Available in Canada

    MONTREAL, Jan. 21 /CNW Telbec/ - Teva Neuroscience Canada announced today
the launch of FROVA(R) (frovatriptan succinate tablets), a unique treatment
for patients suffering from migraines. The single strength 2.5 mg tablets are
now available by prescription in pharmacies throughout Canada. This is
important news for those suffering from migraines who are not receiving
effective therapy at the current time.
    FROVA is indicated for the acute treatment of migraine attacks with or
without aura in adults. "The launch of FROVA in Canada is further proof of
Teva Neuroscience's commitment to patients suffering from neurology
disorders", announced Dr. Jean Godin, General Manager, Teva Neuroscience
Canada. "While there are other treatments currently available for patients
with migraines, our research shows that many patients are not satisfied with
the relief or tolerability offered by the current medications. FROVA has a
unique profile that may benefit many patients."
    Dr. Marek Gawel, a neurologist at Sunnybrook Health Science Center as
well as Women's College that specializes in treating patients with migraines,
was involved in various clinical trials for the drug. "In clinical trials we
have found that the drug offers some unique advantages not found in other
triptans. FROVA provides lasting relief for migraines. This is supported in
the Ryan(1) publication which shows a low headache recurrence, ranging from 7%
to 25%, which resulted in a 24-hour sustained response in up to 51% of
patients taking FROVA. It is likely that the low rates of headache recurrence
appear to be, at least in part, due to FROVA's long half-life of 26 hours. For
patients who respond to the treatment, this means that almost half will be
pain-free for a full 24 hours with few potential side effects."

    About FROVA

    FROVA is approved in Canada for the acute treatment of migraine attacks
with or without aura in adults(2).
    FROVA is not intended for the prophylactic therapy of migraine or for use
in the management of hemiplegic, ophthalmoplegic or basilar migraine. The
safety and effectiveness of FROVA have not been established for cluster
headache, which is present in an older, predominantly male population(2).
    FROVA should only be used when a clear diagnosis of migraine has been
established(2). As with other drugs in this class, FROVA should not be given
to patients with ischemic heart disease(2).
    The most commonly observed side effects are dizziness, paresthesia,
headache, dry mouth, fatigue, flushing, hot or cold sensation, chest pain,
dyspepsia, dysesthesia, throat-tightness and skeletal pain. The recommended
dosage of FROVA is one 2.5 mg tablet. If the headache recurs after initial
relief, a second dose may be taken between 4 and 24 hours after the first
    Frovatriptan is approved in the US (marketed as FROVA(R)) and across
Europe for the acute treatment of migraine and, with a half-life of 26 hours,
has the longest half-life of all the approved drugs in the triptan class.
    Vernalis licensed North American rights to Endo Pharmaceuticals Inc.
which in turn licensed rights to Teva Neuroscience Canada.
    For more information about FROVA, feel free to visit the FROVA Web site
www.frova.ca for product monograph details and other resources to help people
effectively manage migraine.

    About Teva Neuroscience

    Teva Neuroscience is committed to helping people with neurological and
auto-immune disorders live more independent and rewarding lives. Teva
Neuroscience currently offers two other products:

    - Copaxone (glatiramer acetate injection), the first non-interferon drug
      therapy indicated for the treatment of Relapsing-Remitting Multiple
      Sclerosis (RRMS)
    - Azilect (rasagiline mesylate) the only once-daily treatment for
      Parkinson's Disease, approved for both the initial and more advanced
      stages of the disease

    Teva Neuroscience continues to invest in research in various areas of
unmet medical need including: multiple sclerosis,
neurological/neurodegenerative diseases, auto-immune diseases/inflammatory
diseases and oncology.
    Teva Neuroscience Canada has headquarters in Montreal where all
administrative, marketing and other leadership functions are based. There is a
national sales team that supports the needs of physicians across the country.
    Teva Neuroscience represents the branded products for Teva Pharmaceutical
Industries Ltd.
    Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the
top 20 pharmaceutical companies and among the largest generic pharmaceutical
companies in the world. The company develops, manufactures, and markets
innovative and generic human pharmaceuticals and active pharmaceutical
ingredients. Over 80% percent of Teva's sales are in North America and Europe.
    Teva's innovative R&D focuses on developing novel drugs for diseases of
the central nervous system.

    (1) Ryan R, Geraud G, Goldstein J, Cady R, Keywood C. Clinical efficacy
        of frovatriptan: placebo-controlled studies. Headache 2002
        Apr;42 Suppl 2:S84-92.

    (2) FROVA(R) Product Monograph, May 11, 2007.

    FROVA(R) is a registered trademark of Vernalis Development Limited.

For further information:

For further information: Joan Beauchamp, Enigma Communications, (514)
894-2364, j.beauchamp@enigma.ca

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890